MarketCap
Facebook
X
TelegramQuarterly report 2025-Q2
added 08-06-2025
Arcutis Biotherapeutics Operating Income 2011-2026 | ARQT
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Arcutis Biotherapeutics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -128 M | -241 M | -302 M | -207 M | -137 M | -43.1 M | -19.7 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -19.7 M | -302 M | -154 M |
Quarterly Operating Income Arcutis Biotherapeutics
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -14.6 M | -24.5 M | - | -39.1 M | -50.1 M | -31.6 M | - | -36.9 M | -66.8 M | -76.3 M | - | -105 M | -65.8 M | -62.6 M | - | -57.1 M | -42.1 M | -36.1 M | - | -38.3 M | -35.6 M | -28.7 M | - | -14.6 M | -8.54 M | -6.95 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -6.95 M | -105 M | -42.1 M |
Operating Income of other stocks in the Biotechnology industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AgeX Therapeutics
AGE
|
-9.89 M | - | -10.17 % | $ 12.2 K |  USA |
 |
MorphoSys AG
MOR
|
-508 M | - | 2.43 % | $ 254 M |  Germany |
 |
Pharming Group N.V.
PHAR
|
66.7 M | $ 17.07 | -1.28 % | $ 7.59 B |  Niderland |
 |
AlloVir
ALVR
|
-65.4 M | - | 4.14 % | $ 49.1 M | USA |
 |
Biophytis SA
BPTS
|
-26.8 M | - | -13.47 % | $ 169 M |  France |
 |
Can-Fite BioPharma Ltd.
CANF
|
-8.13 M | $ 0.21 | 5.66 % | $ 457 M |  Israel |
 |
Aeglea BioTherapeutics
AGLE
|
-209 M | - | - | $ 1.01 B | USA |
 |
Midatech Pharma plc
MTP
|
-7 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Ascendis Pharma A/S
ASND
|
-452 M | $ 212.56 | -0.32 % | $ 5 B |  Danmark |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
-704 M | $ 10.81 | -4.21 % | $ 699 M | USA |
 |
Aclaris Therapeutics
ACRS
|
-142 M | $ 2.88 | -4.26 % | $ 223 M | USA |
 |
AIkido Pharma
AIKI
|
-11.5 M | - | 1.93 % | $ 17.4 M | USA |
 |
Albireo Pharma
ALBO
|
-123 M | - | -0.23 % | $ 916 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-58.1 M | - | - | $ 2.17 B | USA |
 |
ARCA biopharma
ABIO
|
-88.1 M | - | 1052.0 % | $ 415 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-33.3 M | - | -11.43 % | $ 502 K | USA |
 |
Applied Molecular Transport
AMTI
|
-127 M | - | - | $ 10.1 M | USA |
 |
Acasti Pharma
ACST
|
-16.7 M | - | 4.01 % | $ 150 M |  Canada |
 |
Anika Therapeutics
ANIK
|
-87.6 M | $ 9.41 | -2.08 % | $ 138 M | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
-140 M | - | -15.15 % | $ 60.3 M | Britain |
 |
Athersys
ATHX
|
-87.1 M | - | 3.77 % | $ 22.4 M | USA |
 |
BioNTech SE
BNTX
|
15.3 B | $ 96.62 | 1.49 % | $ 27.2 B | Germany |
 |
Amphastar Pharmaceuticals
AMPH
|
205 M | $ 26.33 | -1.68 % | $ 1.28 B | USA |
 |
Avenue Therapeutics
ATXI
|
-11.3 M | - | -52.27 % | $ 4.45 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
-241 M | $ 1.9 | -4.5 % | $ 485 M | Britain |
 |
AVROBIO
AVRO
|
10.2 M | - | 1083.1 % | $ 745 M | USA |
 |
BioDelivery Sciences International
BDSI
|
37.1 M | - | -4.8 % | $ 255 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
-624 M | - | -6.81 % | $ 3.04 B | USA |
 |
BeiGene, Ltd.
BGNE
|
-568 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Acer Therapeutics
ACER
|
-24.6 M | - | 2.71 % | $ 14 M | USA |
 |
BioVie
BIVI
|
-18.1 M | $ 1.34 | 15.52 % | $ 1.98 M | USA |
 |
Axon Enterprise
AXON
|
58.5 M | $ 563.06 | -0.86 % | $ 42.7 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-37.5 M | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
-7.83 M | $ 2.78 | 6.92 % | $ 17.5 M | USA |
 |
AstraZeneca PLC
AZN
|
1.06 B | $ 91.64 | -0.32 % | $ 96.9 B | Britain |
 |
Bellicum Pharmaceuticals
BLCM
|
-27 M | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
-98.1 M | - | -7.31 % | $ 87 M | USA |
 |
Acorda Therapeutics
ACOR
|
-265 M | - | -24.86 % | $ 820 K | USA |
 |
Brickell Biotech
BBI
|
-6.36 M | - | -5.38 % | $ 6.06 M | USA |
 |
Burford Capital Limited
BUR
|
242 M | $ 8.76 | -1.79 % | $ 1.47 B | Britain |
 |
bluebird bio
BLUE
|
-244 M | - | - | $ 546 M | USA |
 |
Biogen
BIIB
|
7.04 B | $ 177.33 | 0.76 % | $ 25.8 B | USA |
 |
Abeona Therapeutics
ABEO
|
-47.1 M | $ 5.28 | 0.27 % | $ 113 M | USA |
 |
ADiTx Therapeutics
ADTX
|
-27.9 M | $ 0.86 | 3.31 % | $ 11.3 K | USA |
 |
CureVac N.V.
CVAC
|
-412 M | $ 4.66 | 3.1 % | $ 867 M | Germany |